884 related articles for article (PubMed ID: 23300152)
1. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
2. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele JM
J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
[TBL] [Abstract][Full Text] [Related]
3. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R
Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
McBride A; Klaus JO; Stockerl-Goldstein K
Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
Bilotti E
Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib: a novel agent for multiple myeloma.
Redic K
J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
[TBL] [Abstract][Full Text] [Related]
7. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
8. Role of carfilzomib in the treatment of multiple myeloma.
Khan RZ; Badros A
Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
[TBL] [Abstract][Full Text] [Related]
9. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
Jakubowiak AJ
Cancer Treat Rev; 2014 Jul; 40(6):781-90. PubMed ID: 24630735
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
[TBL] [Abstract][Full Text] [Related]
11. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.
Martin TG
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():4-10. PubMed ID: 25184230
[TBL] [Abstract][Full Text] [Related]
12. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
[TBL] [Abstract][Full Text] [Related]
13. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Nooka AK
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():11-8. PubMed ID: 25184231
[TBL] [Abstract][Full Text] [Related]
14. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
15. A practical review on carfilzomib in multiple myeloma.
Muchtar E; Gertz MA; Magen H
Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitors in the treatment of multiple myeloma.
McBride A; Ryan PY
Expert Rev Anticancer Ther; 2013 Mar; 13(3):339-58. PubMed ID: 23477520
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib for the treatment of multiple myeloma.
Lue J; Goel S; Mazumder A
Drugs Today (Barc); 2013 Mar; 49(3):171-9. PubMed ID: 23527321
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Highsmith KN; Chen SE; Horowitz S
Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
Stewart AK
Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
